B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?

Lucas L. van den Hoogen, Radjesh J. Bisoendial*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

8 Citations (Scopus)
61 Downloads (Pure)


Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disease characterized by thrombosis, pregnancy morbidity, and the presence of antiphospholipid antibodies (aPL). Anticoagulants form the mainstay of treatment in PAPS. A growing number of studies suggest a previously underappreciated role of the immune system in the pathophysiology of PAPS. Although B-cells are strongly implicated in the pathophysiology of other autoimmune diseases such as systemic lupus erythematosus (SLE), little is known about the role of B-cells in PAPS. Shifts in B-cell subsets including increases in plasmablasts and higher levels of BAFF are present in patients with PAPS. However, while treatment with rituximab and belimumab may ameliorate thrombotic and non-thrombotic manifestations of PAPS, these treatments do not reduce aPL serum levels, suggesting that B-cells contribute to the pathophysiology of APS beyond the production of autoantibodies.

Original languageEnglish
Article number18
JournalJournal of Clinical Medicine
Issue number1
Publication statusPublished - 20 Dec 2023

Bibliographical note

Publisher Copyright:
© 2022 by the authors.


Dive into the research topics of 'B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?'. Together they form a unique fingerprint.

Cite this